keyword
Keywords Tumor Microenvironment Bone Ma...

Tumor Microenvironment Bone Marrow Chemotherapy

https://read.qxmd.com/read/38510655/tumor-integrin-targeted-theranostic-iron-oxide-nanoparticles-for-delivery-of-caffeic-acid-phenethyl-ester-preparation-characterization-and-anti-myeloma-activities
#1
JOURNAL ARTICLE
Barkley Smith, Yuancheng Li, Travis Fields, Michael Tucker, Anna Staskiewicz, Erica Wong, Handong Ma, Hui Mao, Xinyu Wang
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells preferentially in the bone marrow. Currently, emerging chemotherapy drugs with improved biosafety profiles, such as immunomodulatory agents and protease inhibitors, have been used in clinics to treat MM in both initial therapy or maintenance therapy post autologous hematopoietic stem cell transplantation (ASCT). We previously discovered that caffeic acid phenethyl ester (CAPE), a water-insoluble natural compound, inhibited the growth of MM cells by inducing oxidative stress...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38390333/cd34-dnam-1-bright-cxcr4-haemopoietic-precursors-circulate-after-chemotherapy-seed-lung-tissue-and-generate-functional-innate-like-t-cells-and-nk-cells
#2
JOURNAL ARTICLE
Carola Perrone, Federica Bozzano, Maria Giovanna Dal Bello, Genny Del Zotto, Francesca Antonini, Enrico Munari, Enrico Maggi, Francesca Moretta, Alireza Hajabbas Farshchi, Gianluca Pariscenti, Marco Tagliamento, Carlo Genova, Lorenzo Moretta, Andrea De Maria
BACKGROUND: There is little information on the trajectory and developmental fate of Lin- CD34+ DNAM-1bright CXCR4+ progenitors exiting bone marrow during systemic inflammation. OBJECTIVE: To study Lin- CD34+ DNAM-1bright CXCR4+ cell circulation in cancer patients, to characterize their entry into involved lung tissue and to characterize their progenies. METHODS: Flow cytometric analysis of PBMC from 18 patients with lung cancer on samples collected immediately before the first and the second treatment was performed to study Lin- CD34+ DNAM-1bright CXCR4+ precursors...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38358826/single-cell-analyses-of-metastatic-bone-marrow-in-human-neuroblastoma-reveals-microenvironmental-remodeling-and-metastatic-signature
#3
JOURNAL ARTICLE
Shenglin Mei, Adele M Alchahin, Bethel Tesfai Embaie, Ioana Maria Gavriliuc, Bronte Manouk Verhoeven, Ting Zhao, Xiangyun Li, Nathan Elias Jeffries, Adena Pepich, Hirak Sarkar, Thale Kristin Olsen, Malin Wickström, Jakob Stenman, Oscar Reina-Bedoya, Peter V Kharchenko, Philip J Saylor, John Inge Johnsen, David B Sykes, Per Kogner, Ninib Baryawno
Neuroblastoma is an aggressive pediatric cancer with a high rate of metastasis to the bone marrow. Despite intensive treatments including high-dose chemotherapy, the overall survival rate for children with metastatic neuroblastoma remains dismal. Understanding the cellular and molecular mechanisms of the metastatic tumor microenvironment is crucial for developing new therapies and improving clinical outcomes. Here, we used single-cell RNA-sequencing to characterize immune and tumor cell alterations in neuroblastoma bone marrow metastases by comparative analysis with patients without metastases...
February 15, 2024: JCI Insight
https://read.qxmd.com/read/38253748/a-novel-therapeutic-strategy-the-significance-of-exosomal-mirnas-in-acute-myeloid-leukemia
#4
REVIEW
Ali Salehi
Acute myeloid leukemia (AML) is a fast-growing blood cancer that interferes with the normal growth of blood cells in the bone marrow and blood. It is characterized by its unpredictable outlook and high death rate. The main treatment for AML is chemotherapy, but this often results in drug resistance and the possibility of the disease returning. For this reason, new biomarkers are necessary to diagnose, predict, and treat this disease. Research has demonstrated that cells responsible for AML release exosomes that interact with the disease's microenvironment...
January 23, 2024: Medical Oncology
https://read.qxmd.com/read/38151649/gastric-cancer-and-mesenchymal-stem-cell-derived-exosomes-from-pro-tumorigenic-effects-to-anti-cancer-vehicles
#5
REVIEW
Maryam Dolatshahi, Ahmad Reza Bahrami, Qaiser Iftikhar Sheikh, Mohsen Ghanbari, Maryam M Matin
Gastric cancer (GC) is one of the most prevalent malignancies in the world, with a high mortality rate in both women and men. Conventional treatments, like chemotherapy, radiotherapy and surgery, are facing some drawbacks like acquired drug resistance and various side effects, leading to cancer recurrence and increased morbidity; thus, development of novel approaches in targeted therapy would be very beneficial. Exosomes, extracellular vesicles with a size distribution of sub-150 nm, interplay in physiological and pathophysiological cell-cell communications and can pave the way for targeted cancer therapy...
December 27, 2023: Archives of Pharmacal Research
https://read.qxmd.com/read/38137407/an-overview-on-lipid-droplets-accumulation-as-novel-target-for-acute-myeloid-leukemia-therapy
#6
REVIEW
Clelia Nisticò, Emanuela Chiarella
Metabolic reprogramming is a key alteration in tumorigenesis. In cancer cells, changes in metabolic fluxes are required to cope with large demands on ATP, NADPH, and NADH, as well as carbon skeletons. In particular, dysregulation in lipid metabolism ensures a great energy source for the cells and sustains cell membrane biogenesis and signaling molecules, which are necessary for tumor progression. Increased lipid uptake and synthesis results in intracellular lipid accumulation as lipid droplets (LDs), which in recent years have been considered hallmarks of malignancies...
November 30, 2023: Biomedicines
https://read.qxmd.com/read/38022588/integrated-analysis-of-single-cell-rna-seq-and-bulk-rna-seq-reveals-rna-n6-methyladenosine-modification-associated-with-prognosis-and-drug-resistance-in-acute-myeloid-leukemia
#7
JOURNAL ARTICLE
Zhongzheng Li, Xin Liu, Lan Wang, Huabin Zhao, Shenghui Wang, Guoying Yu, Depei Wu, Jianhong Chu, Jingjing Han
INTRODUCTION: Acute myeloid leukemia (AML) is a type of blood cancer that is identified by the unrestricted growth of immature myeloid cells within the bone marrow. Despite therapeutic advances, AML prognosis remains highly variable, and there is a lack of biomarkers for customizing treatment. RNA N6-methyladenosine (m6 A) modification is a reversible and dynamic process that plays a critical role in cancer progression and drug resistance. METHODS: To investigate the m6 A modification patterns in AML and their potential clinical significance, we used the AUCell method to describe the m6 A modification activity of cells in AML patients based on 23 m6 A modification enzymes and further integrated with bulk RNA-seq data...
2023: Frontiers in Immunology
https://read.qxmd.com/read/38020903/stromal-cell-inhibition-of-anti-cd20-antibody-mediated-killing-of-b-cell-malignancies
#8
JOURNAL ARTICLE
Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J Cheadle, Timothy M Illidge
Introduction: The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse, highlighting the need to understand the mechanisms behind treatment failure to improve patient care. Resistance to chemotherapy is often caused by the ability of malignant B-cells to migrate to the bone marrow and home into the stromal layer...
2023: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/37999904/the-role-of-host-response-to-chemotherapy-resistance-metastasis-and-clinical-implications
#9
REVIEW
Abhilash Deo, Jonathan P Sleeman, Yuval Shaked
Chemotherapy remains the primary treatment for most metastatic cancers. However, the response to chemotherapy and targeted agents is often transient, and concurrent development of resistance is the primary impediment to effective cancer therapy. Strategies to overcome resistance to treatment have focused on cancer cell intrinsic factors and the tumor microenvironment (TME). Recent evidence indicates that systemic chemotherapy has a significant impact on the host that either facilitates tumor growth, allowing metastatic spread, or renders treatment ineffective...
November 24, 2023: Clinical & Experimental Metastasis
https://read.qxmd.com/read/37987679/the-putative-effects-of-neoadjuvant-chemotherapy-on-the-immune-system-of-advanced-epithelial-ovarian-carcinoma
#10
REVIEW
Yunyun Li, Xiaoling Gan, Fei Li, Lina Hu
The epithelial ovarian carcinoma (EOC) is one of leading causes of cancer-related mortality in females. For some patients, complete resection cannot be achieved, thus neoadjuvant chemotherapy (NACT) following interval debulking surgery (IDS) could be an alternative choice. In general-held belief, cytotoxic chemotherapy is assumed to be immunosuppressive, because of its toxicity to dividing cells in the bone marrow and peripheral lymphoid tissues. However, increasing evidence highlighted that the anticancer activity of chemotherapy may also be related to its ability to act as an immune modulator...
November 21, 2023: Immunological Investigations
https://read.qxmd.com/read/37892917/mesenchymal-stem-stromal-cells-immunomodulatory-and-bone-regeneration-potential-after-tumor-excision-in-osteosarcoma-patients
#11
REVIEW
Max Baron, Philip Drohat, Brooke Crawford, Francis J Hornicek, Thomas M Best, Dimitrios Kouroupis
Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor...
October 13, 2023: Bioengineering
https://read.qxmd.com/read/37845689/single-cell-rna-sequencing-distinctly-characterizes-the-wide-heterogeneity-in-pediatric-mixed-phenotype-acute-leukemia
#12
JOURNAL ARTICLE
Hope L Mumme, Sunil S Raikar, Swati S Bhasin, Beena E Thomas, Taylor Lawrence, Elizabeth P Weinzierl, Yakun Pang, Deborah DeRyckere, Chuck Gawad, Daniel S Wechsler, Christopher C Porter, Sharon M Castellino, Douglas K Graham, Manoj Bhasin
BACKGROUND: Mixed phenotype acute leukemia (MPAL), a rare subgroup of leukemia characterized by blast cells with myeloid and lymphoid lineage features, is difficult to diagnose and treat. A better characterization of MPAL is essential to understand the subtype heterogeneity and how it compares with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Therefore, we performed single-cell RNA sequencing (scRNAseq) on pediatric MPAL bone marrow (BM) samples to develop a granular map of the MPAL blasts and microenvironment landscape...
October 16, 2023: Genome Medicine
https://read.qxmd.com/read/37823726/targeted-single-cell-rna-sequencing-analysis-reveals-metabolic-reprogramming-and-the-ferroptosis-resistant-state-in-hematologic-malignancies
#13
JOURNAL ARTICLE
Xiaohui Shen, Peiyuan Dong, Jingjing Kong, Nannan Sun, Fang Wang, Lina Sang, Yan Xu, Mengmeng Zhang, Xiaoli Chen, Rong Guo, Shuya Wang, Quande Lin, Zhongxing Jiang, Shan Xu, Congli Zhang, Zhilei Bian, Weimin Wang, Rongqun Guo
Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell atlas of hematologic malignancies provides novel opportunities for personalized combinatorial targeted treatments, avoiding unwanted chemo-toxicity...
October 12, 2023: Cell Biochemistry and Function
https://read.qxmd.com/read/37798791/mitochondrial-transfer-in-hematological-malignancies
#14
REVIEW
Xiaodong Guo, Can Can, Wancheng Liu, Yihong Wei, Xinyu Yang, Jinting Liu, Hexiao Jia, Wenbo Jia, Hanyang Wu, Daoxin Ma
Mitochondria are energy-generated organelles and take an important part in biological metabolism. Mitochondria could be transferred between cells, which serves as a new intercellular communication. Mitochondrial transfer improves mitochondrial defects, restores the biological functions of recipient cells, and maintains the high metabolic requirements of tumor cells as well as drug resistance. In recent years, it has been reported mitochondrial transfer between cells of bone marrow microenvironment and hematological malignant cells play a critical role in the disease progression and resistance during chemotherapy...
October 5, 2023: Biomarker Research
https://read.qxmd.com/read/37759709/pegylated-liposomal-alendronate-biodistribution-immune-modulation-and-tumor-growth-inhibition-in-a-murine-melanoma-model
#15
JOURNAL ARTICLE
Md Rakibul Islam, Jalpa Patel, Patricia Ines Back, Hilary Shmeeda, Raja Reddy Kallem, Claire Shudde, Maciej Markiewski, William C Putnam, Alberto A Gabizon, Ninh M La-Beck
While tumor-associated macrophages (TAM) have pro-tumoral activity, the ablation of macrophages in cancer may be undesirable since they also have anti-tumoral functions, including T cell priming and activation against tumor antigens. Alendronate is a potent amino-bisphosphonate that modulates the function of macrophages in vitro, with potential as an immunotherapy if its low systemic bioavailability can be addressed. We repurposed alendronate in a non-leaky and long-circulating liposomal carrier similar to that of the clinically approved pegylated liposomal doxorubicin to facilitate rapid clinical translation...
August 26, 2023: Biomolecules
https://read.qxmd.com/read/37666065/interleukin-10-increases-macrophage-mediated-chemotherapy-resistance-via-fabp5-signaling-in-multiple-myeloma
#16
JOURNAL ARTICLE
Mingyue Zhang, Jintong Chen, Hua Zhang, He Dong, Ying Yue, Siqing Wang
Macrophages (MΦs) protect multiple myeloma (MM) cells from chemotherapy-induced apoptosis, and interleukin-10 (IL-10) is frequently elevated in the MM microenvironment. However, the role of IL-10 in MΦ-induced tumor chemotherapy resistance has not yet been clarified. In the present study, bone marrow-derived MΦs were treated with IL-10 (IL10-MΦs), and IL10-MΦ-induced MM chemotherapy resistance was evaluated. IL-10 promoted MΦ-mediated resistance to MM chemotherapy. In addition, IL-10 treatment increased lipid accumulation and fatty acid β-oxidation in MΦs...
November 2023: International Immunopharmacology
https://read.qxmd.com/read/37655401/the-inflamed-niche-a-double-edged-sword-in-aml
#17
EDITORIAL
Livia E Lisi-Vega, Simón Méndez-Ferrer
Although inflammation has long been recognized as a hallmark of many cancers, including acute myeloid leukemia (AML), how it affects individual cells of the tumor microenvironment and their interaction with normal and neoplastic cells is incompletely understood. A comprehensive single-cell transcriptomic analysis of human bone marrow from patients with AML and healthy individuals identified skewing of stem cell and stromal cell populations in AML toward proinflammatory states associated with reduced risk of relapse, paralleling previous findings in mouse models and suggesting that inflamed bone marrow mesenchymal stromal cells might be a double-edged sword in AML by hampering normal hematopoiesis (while AML cells appear comparatively more resilient) but also rendering AML cells more susceptible to chemotherapy or immune attack...
September 1, 2023: Blood cancer discovery
https://read.qxmd.com/read/37638009/case-report-molecular-and-microenvironment-change-upon-midostaurin-treatment-in-mast-cell-leukemia-at-single-cell-level
#18
Meng-Ke Liu, Feng Liu, Yu-Ting Dai, Xiang-Qin Weng, Li-Li Cheng, Li-Quan Fan, Han Liu, Lu Jiang, Xiao-Jian Sun, Hai Fang, Li Wang, Wei-Li Zhao
Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefore, the potential mechanisms of midostaurin resistance and the exact impacts of midostaurin on both gene expression profile and mast cell leukemia microenvironment in vivo are essential for design tailored combination therapy targeting both the tumor cells and the tumor microenvironment...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37601673/chemotherapy-induced-toxic-epidermal-necrolysis-in-a-patient-with-multiple-myeloma-a-case-report-and-literature-review
#19
Rui X, Meidan W, Gongqiang W, Longyi Z, Xiaoxia W, Wei C, Chenhui W
RATIONALE AND PATIENT CONCERNS: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe drug-induced skin reactions associated with a high mortality rate. The patient in this case report developed TEN after receiving the Velcade-lenalidomide-dexamethasone (VRD) regimen for the treatment of multiple myeloma (MM). The patient's concerns included the progression of the rash, pain, itching, and potential long-term complications. TEN is a life-threatening condition that requires prompt medical intervention and hospitalization...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37554265/bcr-abl1-driven-exosome-mir130b-3p-mediated-gap-junction-cx43-msc-intercellular-communications-imply-therapies-of-leukemic-subclonal-evolution
#20
JOURNAL ARTICLE
Chengyan Chai, Ke Sui, Jun Tang, Hao Yu, Chao Yang, Hongyang Zhang, Shengwen Calvin Li, Jiang F Zhong, Zheng Wang, Xi Zhang
Rationale: In the bone marrow microenvironment (BMME), mesenchymal stem/stromal cells (MSCs) control the self-renewal of both healthy and cancerous hematopoietic stem/progenitor cells (HSPCs). We previously showed that in vivo leukemia-derived MSCs change neighbor MSCs into leukemia-permissive states and boost leukemia cell proliferation, survival, and chemotherapy resistance. But the mechanisms behind how the state changes are still not fully understood. Methods: Here, we took a reverse engineering approach to determine BCR-ABL1+ leukemia cells activated transcriptional factor C/EBPβ, resulting in miR130a/b-3p production...
2023: Theranostics
keyword
keyword
159278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.